News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MyoKardia Appoints Biotech Veteran Mark L. Perry To Board Of Directors


11/25/2013 6:53:24 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

MyoKardia, Inc, a company focused on developing innovative therapeutics to treat genetic heart disease, today announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr.

“With more than 30 years of biotechnology experience, Mark brings a wealth of expertise to MyoKardia as we evolve into a fully integrated development company focused on transforming cardiovascular care,” said Tassos Gianakakos, chief executive officer of MyoKardia.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
MyoKardia
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES